Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 171.73 USD 2.37% Market Closed
Market Cap: 303.5B USD
Have any thoughts about
Abbvie Inc?
Write Note

Gross Margin
Abbvie Inc

67.3%
Current
69%
Average
63.7%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
67.3%
=
Gross Profit
37.3B
/
Revenue
55.5B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Abbvie Inc
NYSE:ABBV
303.5B USD
67%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Amgen Inc
NASDAQ:AMGN
155.8B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.1B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
111.8B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
132.3B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
33.8B EUR
89%
KY
Beigene Ltd
SSE:688235
233.5B CNY
84%
Country US
Market Cap 303.5B USD
Gross Margin
67%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 155.8B USD
Gross Margin
60%
Country US
Market Cap 116.1B USD
Gross Margin
86%
Country US
Market Cap 111.8B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 132.3B AUD
Gross Margin
52%
Country US
Market Cap 82B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 33.8B EUR
Gross Margin
89%
Country KY
Market Cap 233.5B CNY
Gross Margin
84%
No Stocks Found

Abbvie Inc
Glance View

Market Cap
303.5B USD
Industry
Biotechnology

AbbVie Inc. is a global biopharmaceutical company that emerged from Abbott Laboratories in 2013, establishing itself as a key player in the healthcare sector with a strong focus on developing innovative therapies. Headquartered in North Chicago, Illinois, AbbVie specializes in immunology, oncology, neuroscience, and virology, boasting a diverse portfolio of products designed to address complex health challenges. Its flagship drug, Humira, has been a cornerstone of the company’s success, contributing significantly to its revenues since it was launched. However, with the expiration of Humira's patent, AbbVie is strategically transitioning its focus toward new treatments, including promising drugs in late-stage development and an expanding pipeline that aims to harness advanced technologies and unique therapeutic approaches. As an investor, AbbVie presents an intriguing opportunity due to its robust commitment to research and development, evidenced by substantial investments that have bolstered its product lineup. The company’s proactive measures to mitigate potential revenue loss from Humira's generics include the acquisition of Allergan in 2020, which expanded its presence in aesthetic medicine and neurology with successful brands like Botox. This move not only diversified its revenue streams but also solidified AbbVie’s competitive position in the biopharmaceutical landscape. With a commitment to delivering long-term value, strong dividend performance, and a focus on innovation, AbbVie is positioned to adapt and thrive amidst the evolving industry dynamics, making it a compelling consideration for investors seeking growth in the healthcare space.

ABBV Intrinsic Value
140.4 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
67.3%
=
Gross Profit
37.3B
/
Revenue
55.5B
What is the Gross Margin of Abbvie Inc?

Based on Abbvie Inc's most recent financial statements, the company has Gross Margin of 67.3%.